Professional Documents
Culture Documents
Kollidon® CL-F
Kollidon® CL-SF
Kollidon® CL-M
Super-disintegrants and dissolution enhancers.
2 The Preface
New: 4 dimensions of The disintegration of a tablet can triggered by their ability to hydro-
Kollidon® CL – standard, be regarded as the initial step in philize insoluble drugs, to stabilize
fine (CL-F), superfine (CL-SF) terms of bioavailability and phar- suspensions and to form com-
and micronized (CL-M) for macological action of the active plexes, as well as by their adsorp-
your individual needs. substance. To achieve rapid disin- tive properties.
Kollidon® is well known as a tegration, a disintegrant normally
universal excipient range since has to be added to the tablet for- BASF supplies Kollidon® CL,
more than 60 years. mulation. The insoluble grades of Kollidon® CL-F and Kollidon®
Kollidon® CL, the cross- Kollidon® are widely used in the CL-SF as disintegrants for the
linked PVP, is not only one of pharmaceuticals industry for this pharmaceutical industry.
the three “super-disintegrants”. purpose. Furthermore, their use Kollidon® CL-M is usually used
Moreover, Kollidon® CL accel- as pharmaceutical excipients is as a suspension stabilizer.
erates the dissolution and the
bioavailability due to its power
to form complexes with many
insoluble actives.
90
80
+ 3 % Kollidon® CL
70
dissolved drug [%]
60
50
40
30
20 without Kollidon® CL
10
0
0 10 20 30 40 50 60
time [min]
The Preface 3
The theory of
disintegration of a tablet
1. Disintegrants are
very hydrophilic.
2. Spherical particles
are uniformly distributed
water in the tablet.
4. They significantly
increase volume and
disintegrate the tablet.
water
Over the past few years, there ing rough surfaces after storage. Furthermore, in new drug delivery
has been a trend towards highly The disintegrants, however, still technologies such as oral dispers-
potent actives (HPAPI) and, as require the power sufficient for a ible tablets, fast disintegrants with
a consequence, a trend towards rapid disintegration. Scientific in- very good mouth feeling are in
smaller tablets. The growth rate vestigation has indicated that the strong demand. Many of these
of 19 % for HPAPIs underlines disintegration power decreases drugs go into pediatric applications
the strong market need for po- with decreasing particle size. This and to the OTC market in general,
tent disintegrants for these ap- can be confirmed by testing our where good patient compliance is
plications. These smaller tablets new materials Kollidon® CL-F and a precondition for the success of a
usually require disintegrants of Kollidon® CL-SF. Although these drug formulation. Based on these
much smaller particle size to materials have smaller particle market trends, our customers will
guarantee content uniformity and sizes, they are still potent disinte- now require new disintegrants for
to prevent the tablets from show- grants. their new applications.
4 The Products
Chemical crosslinks
Entangled polymer
chains (N-vinylpyrro-
lidone-polymer)
A highly (mainly
physically)
crosslinked
polymer matrix
In general, there is no perfect Comparison of the materials Even with a decreased particle
disintegrant. Disintegration is size, the new grades Kollidon®
strongly dependent on the for- The principle property of the CL-F and Kollidon® CL-SF show
mulation of the tablet in terms materials is to decrease the dis- good performance, not having
of porosity, method of manu- integration time of tablets. In the some of the drawbacks that Kolli-
facture (wet or dry granula- figure below the three Kollidon don® CL has, as explained above.
tion) and the use of different grades are compared with their
actives and other excipients. main competitive materials. Apart from the increase in tablet
Clearly, Kollidon® CL shows the disintegration, it is even more im-
strongest performance. portant that the dissolution of the
active ingredient is also increased.
02:09
01:55
01:40
01:26
time [min:sec]
01:12
00:57
00:43
00:28
00:14
00:00
Kollidon® Kollidon® Kollidon® Crospovi- Crospovi- Croscar- Sodium
CL CL-F CL-SF done done mellose- starch
Competitor A Competitor A sodium glycolate
(100–130 µm) (30–50 µm)
The Application 7
90
80
70
drug release [%]
60 ■ Kollidon® CL
■ Kollidon® CL-F
50 ■ Kollidon® CL-SF
■ Crospovidone
40 Competitor A (100–130 µm)
■ Croscarmellose-sodium
30 ■ Crospovidone
20 Competitor A (30–50 µm)
■ Sodium starch glycolate
10
0
0 10 20 30 40 50 60 70 80 90 100 110 120
time [min]
Kollidon® CL
Kollidon® CL
The Application 9
Kollidon® CL-F
Kollidon® CL-F
Kollidon® CL-F is the perfect Capsules filled with microtablets (capsule size 00–4)
alternative when formulators are
looking for a disintegrant with 8.5 mm
strong disintegration power in 5.2 mm
combination with a smooth tablet
surface. With Kollidon® CL,
however, some problems might
23.5 mm
14.1 mm
occur when the tablet is very
hygroscopic and packed in a
multi-dose container.
Kollidon® CL-F
Microtablets,
2 mm diameter
10 The Application
Kollidon® CL-SF
Kollidon® CL-SF
..........
300 µm Kollidon® CL-SF
.......... ..........
50 µm 10 µm
12 The Examples
Nifedipine 10 mg (5.85 %)
Kollidon® VA 64 10 mg (5.85 %)
Ludipress® LCE 100 mg (58.50 %)
Kollidon® CL-F or -SF 50 mg (29.22 %)
Magnesium stearate 1 mg (0.58 %)
Haloperidol 2 mg (2.5 %)
Ludipress® LCE 75 mg (93.75 %)
Kollidon® CL 2.5 mg (3.12 %)
Magnesium stearate 0.5 mg (0.63 %)
As far as disintegrants are con- ensure disintegration. One particu- In the figure, the disintegration
cerned, there are many products lar disadvantage of disintegrants test results of tablets produced
in the market starting with the based on starch and of the cellu- with granulated material are
basic starches derived from maize, lose derivatives is the increase of shown. These clearly show the
rice, corn and potato. They have viscosity after disintegration. The strengths of the crospovidones,
been used for a long time but have first question is always related to especially the Kollidon® CL
certain disadvantages in terms of the real effect of the disintegrant grades.
the amount that is needed to on the disintegration time.
35
33:56
30
disintegration time [min]
25
22:37 23:28
20
15
12:46 12:30
10 11:08
08:55 09:06
0
Kollidon® Kollidon® Kollidon® Kollidon® Crospovi- Crospovi- Croscar- Sodium
CL CL-F CL-SF CL-M done done mellose- starch
Competitor A Competitor A sodium glycolate
(100–130 µm) (30–50 µm)
14 The Overview
Starch derivatives
Cellulose derivatives
Crospovidone grades
*: Not tested
The Summary 15
Company
Address
Country BASF
Aktiengesellschaft
Telephone G-MEP/ME – Li 554
Attn: Dr. Hubertus Folttmann
Fax Carl-Bosch-Straße 64
D-67117 Limburgerhof
e-Mail Germany
Fax Reply
Local contact:
or Headquarter Germany:
+49-621-60-2 86 40
www.pharma-solutions.basf.com
■ Excipients ■ Actives
Kollidon® grades Cremophor ® Ephedrines
Group of povidone grades and Pseudoephedrines
and copovidone Solutol® HS 15 Theophylline
products suitable Range of different Caffeine
mainly as tablet ethoxylated Isotretinoin
binders, emulsifiers and Tretinoin
crospovidone as solubilizers Ibuprofen
tablet disintegrant suitable for topical, Dobutamine
and dissolution oral and parenteral Dopamine
enhancer. formulations. Isometheptene mucate
Kollidon® SR Soluphor ® P Oxymetazoline
Matrix sustained 2-pyrrolidone. PVP-Iodine
release polymer. Lutrol® grades Selegiline
Ludipress® grades Range of PEGs Xylometazoline
Direct tabletting (Lutrol® E range)
aids for faster and poloxamers APIs by Orgamol
product develop- (Lutrol® F range)
ment and speedier for a wide variety Vitamins
processing. of pharmaceutical
Kollicoat ® grades dosage forms. ■ Contract
Range of aqueous Manufacturing
based film formers,
cost efficient and ■ Value Added
ecological.